Sera Prognostics Inc - Ordinary Shares Class A ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Sera Prognostics Inc - Ordinary Shares Class A zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Sera Prognostics Inc - Ordinary Shares Class A zu Deinem Portfolio hinzuzufügen.
Sera Prognostics Inc - Ordinary Shares Class A Aktie News
SALT LAKE CITY , Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, ...
SALT LAKE CITY , Aug. 28, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright 27th Annual Global Investment Conference on Friday, September 5, 2025 at 7:00 a.m.
Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Austin Aerts - Chief Financial Officer Evguenia Lindgardt - President, CEO & Director Conference Call Participants Margarate Elizabeth Boeye - William Blair & Company L.L.C., Research Division William Ruby - TD Cowen, Research Division Peter DeNardo - Unidentified Company Operat...
Sera Prognostics (SERA 12.24%), a diagnostic company specializing in pregnancy risk prediction, reported Q2 2025 results on August 6, 2025. The company's headline news was a net loss improvement and continued strategic investment toward commercial rollout, despite revenue remaining extremely modest.
SALT LAKE CITY , Aug. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2025 ended June 30, 2025. Second Quarter and Recent Highlights: Ongoing progress in engaging Medic...
SALT LAKE CITY , July 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2025 financial results on Wednesday, August 6, 2025, after the close of the market. The Comp...
Sera Prognostics' PreTRM test shows strong clinical utility in reducing neonatal morbidity and NICU admissions, outperforming standard cervical length screening. The company is well-capitalized with $114 million in cash, sufficient to fund commercialization efforts into 2028, despite current losses. Key growth drivers include commercial reimbursement, Medicaid coverage, and inclusion in clinica...
SALT LAKE CITY , May 29, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conferen...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.